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A B S T R A C TObjectives: We described previously the development of a set of
quality indicators (QIs) of a childhood cancer system in Ontario,
Canada. The purpose of this study was to determine the acceptability
of the proposed set of QIs among stakeholders of the childhood cancer
system. Methods: A modiﬁed Delphi method was used to assess
stakeholder agreement on the value of the proposed QIs. A QI
evaluation survey was mailed to a stakeholder group of 23 multi-
disciplinary health care providers, survivors, parents, and policy-
makers who rated each QI on speciﬁc criteria. Prior to an in-person
consensus meeting, the distribution of scores was provided to panel
members. At the meeting, QIs were reevaluated and discussed in
three successive rounds. QIs with 80% or more of panel agreement
were considered endorsed. Results: Overall, 20 QIs were endorsed by
the panel, measuring all seven quality dimensions of Ontario’s Cancer
System Quality Index framework. Five QIs were endorsed by 100% ofsee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.02.016
erg@pogo.ca.
ndence to: Mark L. Greenberg, Pediatric Oncology Gthe panel as follows: Five-year event-free survival, chemotherapy
admission delay, drug availability, sufﬁcient multidisciplinary staff,
and parent satisfaction. Although none of the QIs relating to end-of-
life or Satellite care were endorsed, panel members emphasized the
need to measure these components of the system. Conclusions:
Standardized implementation of the 20 pediatric cancer QIs endorsed
by the multidisciplinary stakeholder panel will provide ongoing mon-
itoring of various dimensions of system quality and the development
of benchmarks over time, greatly augmenting the ability to identify
needed system improvements across populations and jurisdictions.
Keywords: consensus, Delphi technique, health care, neoplasm,
pediatric, quality improvement, quality indicators.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Although cancer remains the most common disease-related
cause of death among children in North America [1–4], there is
no well-deﬁned set of quality indicators (QIs) of a childhood
cancer system against which any system can be compared. QIs
can be used to inform and inﬂuence policy or funding, alter
clinical practices and behaviors of health care providers, increase
the general understanding in the community, and improve the
quality of the system [5]. For most areas of health service
delivery, quality assessment is evidence-based, yet limited evi-
dence exists for quality measurement in pediatric oncology [6,7].
While QIs and quality assessment frameworks for the cancer
control system for adults have been developed [8,9], a set of
indicators to assess the quality of a childhood cancer system has
not been identiﬁed in any jurisdiction in Canada or internation-
ally [6,7].
The Pediatric Oncology Group of Ontario (POGO) is a collabo-
rative consortium of the ﬁve specialty pediatric cancer programs
in academic tertiary hospitals in Ontario, Canada, and thecommunity hospitals and cancer centers that deliver POGO
provincial pediatric oncology programs. These programs include
a system of Satellites, providing devolved care, AfterCare clinics,
for the long-term follow-up of pediatric and adult survivors, and
expert pediatric oncology Interlink Community Nurses (who
support children and families in the hospital, community, and
at home). POGO is mandated to identify areas for cancer system
development to the provincial Ministry of Health and Long-Term
Care (MOHLTC) and operates in ongoing collaboration with
families of children with cancer, survivors, corporate and private
benefactors, and volunteers. Since 1985, the organization has
actively and prospectively collected standardized sociodemo-
graphic, diagnostic, therapeutic, and outcome data on each new
case of childhood cancer diagnosed and treated in the province
through its population-based Networked Information System
(POGONIS) [10].
In a companion study [6], we report the development of a
proposed QI set for the childhood cancer system in Ontario on the
basis of a systematic literature review and expert consensus. QIs
were to be scientiﬁcally sound and valid, reﬂect an importantociety for Pharmacoeconomics and Outcomes Research (ISPOR).
roup of Ontario, 480 University Avenue, Suite 1014, Toronto, ON,
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improvement and health care accountability, aligned with the
childhood cancer mission and strategic objectives of the system,
interpretable and feasible, address a priority area, and mean-
ingful and of interest to key parties [6]. The purpose of the current
study was to assess the acceptability of the proposed set of QIs
for the childhood cancer system among provincial stakeholders.Methods
A modiﬁed Delphi process was used to assess stakeholder agree-
ment on, and acceptability and prioritization of, 33 proposed QIs.
This is a validated method using structured facilitation to obtain
feedback and determine group consensus by synthesizing opin-
ions [11–13] “when published information is inadequate or non-
existent” [14]. This study received approval by the Research
Ethics Board at McMaster University, Ontario, Canada.
QI Selection
In a companion study [6], a subset of 33 QIs was developed (see
Appendix B of companion study in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2013.02.016), measuring the
seven quality dimensions of the Cancer System Quality Index
(CSQI) framework (see Table 4 of companion study) [15].
Modiﬁed Delphi Panel Assembly
A panel of 23 individuals representing each of the key stake-
holder groups was invited to participate. These groups were
multidisciplinary health care providers, who may use the ﬁnd-
ings to improve the quality of care provided to children with
cancer; childhood cancer programs, which will implement QIs
and adapt to ﬁndings; survivors of childhood cancer and parents
of children who had cancer, who may use the ﬁndings to raise
awareness, promote advocacy, and make informed health care
decisions; and policymakers and decision makers, who are
interested in system performance measurement and monitoring.
Purposive sampling was used to select at least one represen-
tative from each stakeholder group. Provincial representation
was sought whereby each of the ﬁve tertiary programs nomi-
nated one individual from each of the following discipline groups:
physician, nurse, behavioral practitioner, allied health professio-
nal, and administrative/hospital manager. Tertiary programs also
selected one “must-have” individual to represent each program.
The ﬁnal panel consisted of 23 participants: 17 health care
providers, including six pediatric oncologists, a pediatrician from
the Satellite program, four nurses from tertiary, Satellite, and
Interlink programs, four behavioral practitioners (two social
workers, one neuropsychologist, and one clinical psychologist),
and two allied health professionals (one pharmacist and one
physiotherapist); two tertiary hospital administrators/managers;
one adult survivor of childhood cancer; two parents; and one
policymaker from the Ontario MOHLTC.
Mailed Survey
Each panel member was mailed a survey and rated each QI on
two criteria (meaningfulness and importance) by using a seven-
point Likert scale (where 1 ¼ “not meaningful” or “not important”
and 7 ¼ “very meaningful” or “very important”). The two criteria
items for QI scoring were adapted on the basis of a recent
modiﬁed Delphi process assessing stakeholder acceptability of
adult cancer end-of-life care QIs [16] and assessed the mean-
ingfulness (Does the indicator truly measure an aspect of Ontar-
io’s pediatric cancer system?) and importance (Does this
indicator reﬂect an important issue for this system?) of each QI.The survey presented each QI with operational deﬁnitions,
rationale for selection as a potential system QI, and measure-
ment speciﬁcations (Fig. 1). Panelists were also able to provide
comments on each QI.
Modiﬁed Delphi Panel Consensus Meeting
A full-day, in-person, multiround, iterative consensus meeting,
facilitated by an external consultant, was undertaken to assess
stakeholder agreement and acceptability of the 33 QIs. One week
prior to the meeting, individualized scoring reports were mailed
to each panel member, containing aggregate and individual
respondent scores for each QI. Panel comments were also
summarized anonymously in the reports.
At the meeting, panelists were presented with key consider-
ations for QI endorsement. First, QIs were to be endorsed on the
basis of their meaningfulness and importance. To capture highly
important, relevant, and meaningful QIs, including those for
which standardized data collection may not yet be established,
issues of feasibility and resource implications were not to be
considered. Panel members were also asked to use a systems-
level perspective in evaluating QIs, rather than an individual
center or health care provider perspective. Although a speciﬁc
target number of QIs was not set, a high level of panel agreement
was desired.
During each round of QI rating and discussion, panelists were
asked to select QIs that they would endorse as an indicator of the
quality of Ontario’s childhood cancer system. Anonymous
responses were provided on individual electronic devices, aggre-
gated, and displayed. QIs approved by at least 80% of the panel
were considered endorsed.
Analysis
Means, medians, and SDs of survey scores were calculated for
both meaningfulness and importance by using Statistical Analy-
sis System software (version 9.1). For each QI and each criterion,
scores of 6 to 7 were categorized as “very meaningful/very
important,” 3 to 5 as “neutral meaningfulness/neutral impor-
tance,” and 1 to 2 as “not meaningful/not important,” and the
percentage distribution for each score was generated.
Based on the mailed survey, panel agreement was assessed by
using a disagreement index, calculated as the 30th to 70th
interpercentile range divided by the interpercentile range
adjusted for symmetry, as deﬁned by the RAND working group
[13,17]. This disagreement index describes the dispersion of
individual scores, with scores of more than 1 indicating disagree-
ment. Levels of panel agreement were also established on the
basis of the proportion of panelists who scored the QI within one
of the three categories of meaningfulness and/or importance,
where 70% or more of panel members scoring within one
category of meaningfulness/importance indicated “high agree-
ment,” 60% to less than 70% indicated “moderate agreement,”
and 50% to less than 60% indicated “low agreement.” The
discussions were audiotaped, transcribed verbatim, and reviewed
for common themes.Results
Mailed Survey
Overall, 22 surveys were completed (96% response rate)—one
panel member (parent) declined participation because of time
constraints. Figure 2 summarizes the initial survey rating of the
33 QIs on their overall levels of meaningfulness and importance.
QIs were scored highly, with a median score range of 4.5 to 7
(Table 1). Based on median scores, 19 QIs (58%) were rated as
30. Actual Drug and Dose Errors
Indicator Definition:  The number of actual drug or dose errors for pediatric oncology patients on active treatment. 
For a definition of “Active Treatment,” please see the Glossary.
Indicator Specification: Proportion
• Numerator:   Total number of actual drug or dose errors for pediatric oncology patients on active treatment. 
• Denominator:   Total number of pediatric oncology patients on active treatment.
Indicator Rationale:  Pediatric oncology patients on active therapy are prescribed a range of medications including 
drugs with significant toxicity and narrow therapeutic margins.  This indicator will provide an index of the 
frequency with which actual medication errors occur (i.e., the incorrect drug or dose is administered to the patient).
Please rate this indicator in terms of the following statements, where 1 indicates that that the indicator is ‘Not 
Meaningful/Important’ and 7 indicates that the indicator is ‘Very Meaningful/Important.’
Not Meaningful Very Meaningful
1. Meaningfulness: Does this indicator truly 
measure an aspect of the quality of Ontario’s 
pediatric oncology system?
1 2 3 4 5 6 7
Not Important Very Important
2. Importance: Does this indicator reflect an 
important issue for this system? 1 2 3 4 5 6 7
Comments: 
Other Indicator Technical Specifications:
• Source of Data:  Hospital Incident Reports
• Levels of Analysis to be Reported:  
a. Overall Provincial 
b. By Tertiary Centre
c. By Type of Drug (i.e. Chemotherapy vs. Non-Chemotherapy Drug)
• Sampling Timeframe:  12-month period
• Interpretation of Score/ Directionality:  Better quality is associated with a lower rate of actual drug or dose 
errors.
Fig. 1 – Sample page from mailed Delphi panel survey.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 6 3 9 – 6 4 6 641“both very meaningful and very important” (median scores of 6–7),
six QIs (18%) as “either very meaningful or very important”
(median scores of 6–7) and “neutral” (median scores of 3–5) on
the other criteria, and eight (24%) as “neutral meaningfulness and
neutral importance” (median scores of 3–5). None of the QIs were
considered to be “neither meaningful nor important” (median
scores of 1–2) (Table 1).
Fourteen QIs (42%) had a disagreement index of less than 1.0
(range 0.00–0.71) on either meaningfulness or importance, indi-
cating a high level of panel agreement (Table 1). Agreement on
meaningfulness and importance ratings was aligned closely, with
the exception of ﬁve QIs: actual drug/dose errors, treatment-
related mortality, adolescent cancer diagnosis in a pediatric
center, guidelines for nutritional support, and end-of-life care
days spent in acute care. While the panel indicated actual drug/
dose errors, treatment-related mortality and adolescent cancer
diagnosis in a pediatric center to be important issues for the
system, they did not agree that these QIs measured quality;
conversely, guidelines for nutritional support and end-of-life care
days spent in acute care were considered to measure system
quality, but, according to the panel, they did not reﬂect important
system-level issues.Recurrent comments indicated the need for clariﬁcation of QI
purposes, deﬁnition, and evaluation methodologies. For instance,
some individual center-level perspectives were provided, rather
than a provincial, systems-level view, such as “this [indicator
construct] is not a signiﬁcant issue at my centre” or “my hospital
would not score well on this indicator.” Issues surrounding the
comprehensiveness of the QI construct were also highlighted. For
example, some comments suggested that a given QI would not
measure all variations of a particular construct and would there-
fore not be a comprehensive quality measure (e.g., “Interlink is
not the only provider of palliative care”). Feasibility of data
collection and reporting issues were also noted by the panel,
including the potential human resource implications (e.g., “data
collection would be too labour intensive”).
QI Rating based on Consensus Meeting
The consensus meeting consisted of three iterative rounds of QI
rating and discussion. All 22 panelists who completed the
surveys attended the consensus meeting, 3 weeks after returning
completed surveys. Table 2 summarizes the results of the meet-
ing, with 20 QIs endorsed by the panel overall. Seventeen QIs
0%   20%   40%   60%   80% 100%  20%   40%  60%  80% 100%
0%  
IMPORTANCE MEANINGFULNESS
Fig. 2 – Initial ranking* of mailed survey scores on the meaningfulness and importance of the proposed quality indicators of
the childhood cancer system. ICU, intensive care unit; PET, positron emission tomography; RT, radiation therapy.
*Ranking based on the rating scores on the importance of each of the 33 quality indicators.
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panel agreement. Five QIs had complete (100%) panel endorse-
ment (Table 2).
A second round followed for the remaining 16 QIs. Panelists
were asked to select up to eight QIs that they would endorse.
Seven QIs were not endorsed and thus eliminated (Table 2). The
remaining nine QIs were evaluated during a third and ﬁnal round.
Three of the nine QIs were endorsed (Table 2). Overall, the panel
endorsed at least one QI for each of the seven CSQI quality
dimensions (Table 3).Discussion
This study used a modiﬁed Delphi process to evaluate a set of QIs
for a childhood cancer system in Ontario, Canada. Each succes-
sive round provides the opportunity to revise individual judg-
ments in line with the average group scores, and therefore, data
may be more informative and valid than individual opinions[11,12,18]. Overall, 20 QIs distributed across the seven CSQI
quality dimensions were endorsed by at least 80% of panel
members. The high level of endorsement (i.e., ≥80%) was selected
to ensure a high level of stakeholder community buy-in for QI
implementation. A balanced perspective on the panel was
sought, with provincial representation from diverse stakeholder
groups, including multidisciplinary health care providers from all
levels of care (tertiary and community), parents, survivors, and
policymakers. Based on the recommendation of the Delphi panel
facilitator, with expertise in group consensus development, the
size of the panel was limited to 23 to optimize the desired group
consensus process.
Overall, there was a high degree of alignment of opinions
between mailed survey scores and consensus meeting ratings: 16
of the 19 QIs (84%) scored as “highly meaningful and highly
important” in the survey were endorsed by the panel. Further-
more, seven of the eight QIs scored as “neutral meaningfulness
and neutral importance” in the mailed survey were not endorsed
by the panel. Five-year event-free survival had the highest level
Table 1 – Initial Delphi Panel ratings on meaningfulness and importance and acceptability of quality indicators
based on mailed survey.*
Quality indicator Meaningfulness Importance
Median score
(range)
% Agreement
(disagreement index)†
Median score
(range)
% Agreement
(disagreement index)†
QIs with demonstrated agreement‡ (n ¼ 14)
Five-year event-free survival 7.0 (4–7) 86 (0.71) 7.0 (5–7) 96 (0.00)
Five-year overall relative survival 7.0 (3–7) 77 (0.71) 7.0 (4–7) 86 (0.71)
First therapeutic intervention wait
time
6.0 (4–7) 82 (0.71) 7.0 (5–7) 86 (0.71)
Time taken for pathology report
production
6.5 (3–7) 73 (0.71) 6.5 (4–7) 82 (0.71)
Sufﬁcient multidisciplinary staff 6.0 (5–7) 82 (0.71) 6.0 (4–7) 82 (0.71)
Chemotherapy admission delay 6.0 (4–7) 77 (0.00) 6.0 (5–7) 73 (0.71)
Clinical trial participation 6.0 (4–7) 73 (0.00) 6.0 (4–7) 77 (0.00)
Actual drug/dose errors§ 6.0 (4–7) 64 (10.00) 6.0 (3–7) 73 (0.00)
Treatment-related mortality§ 6.0 (3–7) 55 (10.00) 6.0 (4–7) 73 (0.71)
Adolescent cancer diagnosis in
pediatric center§
6.0 (3–7) 55 (10.00) 6.0 (4–7) 73 (0.00)
Shuttle sheet 5.0 (3–6) 91 (0.00) 5.0 (2–6) 77 (0.63)
After hours cancer surgery 5.0 (3–7) 73 (0.63) 4.5 (3–7) 77 (0.63)
Guidelines for nutritional support|| 5.0 (3–7) 73 (0.63) 5.0 (3–7) 59 (10.00)
End-of-life care days spent in acute
care||
4.5 (3–7) 82 (0.63) 5.0 (3–7) 54 (10.00)
QIs with demonstrated disagreement (n ¼ 19)
Parent/guardian satisfaction 6.0 (4–7) 68 (3.08) 6.5 (4–7) 68 (3.08)
Supportive care guidelines 6.0 (4–7) 68 (3.08) 6.0 (3–7) 68 (3.08)
Use of conformal or intensity-
modulated RT
6.0 (2–7) 68 (10.00) 6.0 (4–7) 64 (3.08)
Drug availability 6.0 (3–7) 59 (10.00) 6.0 (3–7) 68 (3.08)
Case coordinator 6.0 (3–7) 54 (3.08) 6.0 (3–7) 68 (3.08)
Eligible survivors enrolled in
AfterCare
6.0 (5–7) 64 (10.00) 6.0 (4–7) 64 (10.00)
Tumor boards 6.0 (1–7) 59 (10.00) 6.0 (1–7) 64 (10.00)
Access to expert management for
pain control
6.0 (1–7) 64 (10.00) 6.0 (2–7) 54 (10.00)
Central venous line infection rate 6.0 (4–7) 59 (10.00) 6.0 (3–7) 59 (10.00)
Access to PET scanning 6.0 (3–7) 59 (10.00) 5.5 (3–7) 50 (10.00)
Wait time: Sedation for ambulatory
procedures
6.0 (2–7) 59 (10.00) 5.5 (4–7) 50 (10.00)
Major clinical trial protocol violation 6.0 (2–7) 59 (10.00) 5.5 (2–7) 50 (10.00)
Eligible patients enrolled in Satellite 5.0 (3–7) 54 (10.00) 6.0 (4–7) 64 (10.00)
ICU admissions due to neutropenic
sepsis
5.0 (3–7) 64 (10.00) 6.0 (3–7) 59 (10.00)
Potential drug/dose errors 5.0 (2–7) 50 (2.35) 6.0 (2–7) 54 (10.00)
Survivors with a survivor care plan 5.5 (3–7) 50 (10.00) 5.5 (4–7) 50 (10.00)
Chemotherapy certiﬁcation of
nursing staff
5.0 (4–7) 54 (10.00) 5.5 (4–7) 50 (10.00)
Interdisciplinary team meetings 5.0 (3–7) 64 (10.00) 5.0 (2–7) 59 (2.35)
Patients referred for end-of-life
Interlink care
5.0 (3–7) 64 (10.00) 5.0 (3–7) 54 (10.00)
ICU, intensive care unit; PET, positron emission tomography; QIs, quality indicators; RT, radiation therapy.
 Indicators are stratiﬁed according to demonstrated agreement or disagreement and further rank ordered by median score and highest
percentage agreement on meaningfulness or importance.
† Disagreement index, as deﬁned by the RAND working group, where index scores 41 indicate disagreement.
‡ Based on the results of the mailed Delphi panel survey, agreement was established as ≥70% on meaningfulness and/or importance or a
disagreement index of ≤1.0.
§ Demonstrated agreement on importance only.
|| Demonstrated agreement on meaningfulness only.
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meeting. Although both potential and actual drug and dose error
QIs were endorsed by the panel at the conclusion of theconsensus meeting, some panel members initially had concerns
with respect to the potential drug and dose errors QI, as identiﬁed
by the lack of consensus of survey scoring results, as well as the
Table 2 – Summary of quality indicator acceptability by the Delphi Panel based on the multiround consensus
meeting.
Consensus
round*
QIs endorsed by Delphi panel† (N
¼ 20 QIs)
QIs for further consideration and
discussion by Delphi panel
QIs not endorsed by Delphi
panel (N ¼ 13 QIs)
Round 1
(N ¼ 33 QIs)
n ¼ 17 QIs n ¼ 16 QIs n ¼ 0 QIs
 Five-year event-free survival (100%)
 Chemotherapy admission
delay (100%)
 Drug availability (100%)
 Sufﬁcient multidisciplinary
staff (100%)
 Parent/guardian satisfaction (100%)
 First therapeutic intervention wait
time (95%)
 Actual drug/dose errors (95%)
 Access to expert pain
management (95%)
 Time to pathology report
production (95%)
 Treatment-related mortality (90%)
 Clinical trial participation (90%)
 Case coordinator (86%)
 Five-year overall relative
survival (86%)
 Eligible survivors enrolled in
AfterCare (86%)
 Adolescent cancer diagnosis in a
pediatric center (81%)
 Wait time: Sedation for ambulatory
procedures (81%)
 Supportive care guidelines (81%)
 Access to PET scanning (76%)
 Survivors with a survivor care plan (71%)
 Use of conformal or intensity-modulated
RT (71%)
 Major clinical trial protocol violation (71%)
 Eligible patients enrolled in Satellite (67%)
 ICU admissions due to neutropenic
sepsis (67%)
 Tumor boards (62%)
 Guidelines for nutritional support (57%)
 Chemotherapy certiﬁcation of nursing
staff (57%)
 CVL infection rate (57%)
 Potential drug/dose errors (52%)
 Patients referred for end-of-life Interlink
care (48%)
 End-of-life care days spent in acute
care (38%)
 Interdisciplinary team meetings (38%)
 After hours cancer surgery (33%)
 Shuttle sheet (29%)
Round 2
(N ¼ 16 QIs)
n ¼ 0 QIs n ¼ 9 QIs n ¼ 7 QIs
 Access to PET scanning (78%)
 Survivors with a survivor care plan (78%)
 Potential drug/dose errors (78%)
 Eligible patients enrolled in Satellite (74%)
 Chemotherapy certiﬁcation of nursing
staff (74%)
 Shuttle sheet (70%)
 Interdisciplinary team meetings (39%)
 Tumor boards (22%)
 Major clinical trial protocol violation (13%)
 Patients referred for end-of-life
Interlink care (48%)
 End-of-life care days spent in
acute care (38%)
 CVL infection rate (30%)
 Use of conformal or intensity-
modulated RT (25%)
 ICU admissions due to
neutropenic sepsis (10%)
 After hours cancer surgery (10%)
 Guidelines for nutritional
support (0%)
Round 3
(N ¼ 9 QIs)
n ¼ 3 QIs n ¼ 0 QIs n ¼ 6 QIs
 Survivors with a survivor care
plan (95%)
 Access to PET scanning (90%)
 Potential drug/dose errors (85%)
 Chemotherapy certiﬁcation of
nursing staff (75%)
 Eligible patients enrolled in
Satellite (75%)
 Shuttle sheet (75%)
 Interdisciplinary team
meetings (60%)
 Tumor boards (25%)
 Major clinical trial protocol
violation (10%)
CVL, central venous line; ICU, intensive care unit; PET, positron emission tomography; QIs, quality indicators; RT, radiation therapy.
 Indicates the iterative round of the ranking and discussion of QIs by the Delphi panel.
† QIs were considered endorsed by the Delphi panel during the consensus meeting when there was ≥80% panel agreement.
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Table 3 – Quality indicators of the Childhood Cancer
System endorsed by the Delphi panel (and propor-
tion of stakeholder agreement) (n ¼ 20), by CSQI
quality dimension.
Safe (n ¼ 2) Effective (n ¼ 5)
 Actual drug/dose
errors (95%)
 Potential drug/
dose errors (95%)
 Five-year event-
free
survival (100%)
 Treatment-related
mortality (90%)
 Access to PET
scanning (90%)
 Five-year overall
relative
survival (86%)
 Supportive care
guidelines (81%)
Integrated (n ¼ 3) Responsive (n ¼ 1)
 Survivors with a survivor care plan (95%)
 Eligible survivors enrolled in
AfterCare† (86%)
 Case coordinator (86%)
 Parent/guardian
satisfaction (100%)
Accessible (n ¼ 7) Equitable (n ¼ 2) Efﬁcient (n ¼ 5)
 Chemotherapy
admission
delay (100%)
 Sufﬁcient
multidisciplinary
staff (100%)
 First therapeutic
intervention wait
time (95%)
 Access to expert
management of
pain control (95%)
 Clinical trial
participation (90%)
 Wait time:
Sedation for
ambulatory
procedures (81%)
 Adolescent cancer
diagnosis in a
pediatric
center‡(81%)
 Eligible survivors
enrolled in
AfterCare† (86%)
 Adolescent
cancer diagnosis
in a pediatric
center‡ (81%)
 Drug
availability (100%)
 Time taken for the
production of
pathology
reports (95%)
 Survivors with a
survivor care
plan* (95%)
 Eligible survivors
enrolled in
AfterCare† (86%)
 Adolescent cancer
diagnosis in a
pediatric
center‡ (81%)
CSQI, Cancer System Quality Index; PET, positron emission
tomography.
 This indicator is assigned to the Integrated and Efﬁcient quality
dimensions.
† This indicator is assigned to the Integrated, Equitable, and
Efﬁcient quality dimensions.
‡ This indicator is assigned to the Accessible, Equitable, and
Efﬁcient quality dimensions.
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tion and potential bias in self-reporting by hospitals or health
care providers were emphasized by the panel. The potential drug
and dose error QI, however, was endorsed for the childhood
cancer system in Ontario by the third round of the consensus
process, as this was considered to be an important area of patient
safety and system quality, warranting standardized provincial
data collection and monitoring.Overall, 13 QIs were not endorsed by the panel. Although the
proposed QIs spanned the childhood cancer care trajectory and
levels of care, the panel did not endorse the speciﬁc QIs proposed
pertaining to end-of-life (i.e., patients referred for end-of-life
Interlink care and end-of-life care days spent in acute care) or
devolved Satellite care (i.e., eligible patients enrolled in Satellite
and Shuttle Sheet). Some individuals emphasized that the two
proposed end-of-life care QIs did not broadly capture key issues
of quality end-of-life care for children with cancer. Similarly, the
panel questioned the content validity and selected measures of
quality for the provincial Satellite system. The principle that a QI
measures only one aspect of a concept area referable to system
performance required emphasis to ensure that the panel had an
accurate understanding of the task. Further work is needed on
how to best measure the quality of end-of-life and Satellite care
for Ontario’s childhood cancer system, particularly because the
panel emphasized the integral nature of both to system quality.
The degree of support for any given QI may be inﬂuenced by
multiple factors, including the composition of the panel, the ease
of data collection to validate the QI, and its perceived impact.
Some QIs were not endorsed by the panel, who believed that the
QIs would not detect important gaps in the system nor address a
priority area where additional resources and/or interventions may
have an impact leading to system improvements. Chemotherapy
certiﬁcation of nursing staff and use of conformal or intensity-
modulated radiation therapy QIs were not endorsed, as the panel
believed that although these QIs measure standards of care for
Ontario’s childhood cancer system, they are already well estab-
lished and implemented provincially. Furthermore, two other QIs,
including clinical trial protocol violation and central venous line
infection rate, were not endorsed by the panel, who felt that both
areas are already systematically monitored by various regulatory
groups, such as the Children’s Oncology Group (for clinical trial
protocol violations), and by every hospital in Ontario and the
provincial MOHLTC (for central line infections) and would not
detect any additional areas of required system improvement.
Although this study was conducted to evaluate stakeholder
consensus of a set of QIs of a childhood cancer system, the
modiﬁed Delphi process used to generate group consensus, as
well as some of the QIs endorsed by the Delphi panel, such as
actual and potential drug/dose errors, may be applicable to a
broader range of pediatric clinical practice and policy areas beyond
childhood cancer. To ensure the efﬁcacy of QI development and
endorsement, Delphi panels must be briefed and educated on QI
methodologies to understand and support quality improvement
processes more fully [16]. Although panel members were pre-
sented with an overview of key considerations for QI endorse-
ment, it is difﬁcult to determine whether QIs were evaluated free
of any individual or center-speciﬁc biases. It is possible that some
panel members were disproportionately biased by other members
who were more vocal or inﬂuential due to their experience level
and positions, a group phenomenon also described by Guttmann
et al. [19]. Utilization of a group facilitator, who ensured that all
panel members had the opportunity to express their opinions, and
panel member selection to ensure representation from diverse
stakeholder groups were methods utilized to minimize this poten-
tial threat to internal validity. We recommend that both content
expert(s) and external Delphi cofacilitator(s) are needed to ensure
important explanation and context, while limiting undue group
inﬂuence. Prior to and during QI implementation, ongoing and
targeted communication of QI purposes, rationales, results, and
interpretations, as well as stakeholder education, is essential to
ensure that stakeholders are engaged in quality improvement
processes and fully understand the intent, purpose, and use of QIs
as ongoing tools for evaluation and improvement of the system.
Within Ontario, another effort to implement a cancer system
quality measurement strategy is Ontario’s CSQI [9]. Published
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 6 3 9 – 6 4 6646annually since 2005, the CSQI reports on 41 QIs of the adult
provincial cancer system, ranging from cancer prevention and
screening to diagnosis, treatment, survival, and end-of-life care,
and tracks progress against provincially established standards in
Ontario across the seven quality dimensions of the CSQI, including
safety, effectiveness, responsiveness, integration, accessibility,
equity, and efﬁciency [9]. Although the CSQI framework was adopted
for the childhood cancer system, as it was considered to best
encompass the key quality dimensions of the childhood cancer
system in Ontario and would allow for comparability between
provincial pediatric and adult cancer systems [6], the marked
differences in the cancer control spectrum for the childhood
population compared with adults limit the applicability of the
speciﬁc QIs of the CSQI to the childhood cancer system. For instance,
the CSQI includes indicators on the primary and secondary preven-
tion of selected cancers, including the prevalence of modiﬁable risk
factors, such as smoking, obesity, and alcohol consumption, and
breast, prostate, and cervical cancer screening [9]. Primary and
secondary prevention of childhood cancer, however, is not yet
possible because no known modiﬁable risk factors or screening
exist. Furthermore, some QIs of the CSQI, such as wait times from
diagnosis to chemotherapy, are stratiﬁed by speciﬁc types of cancer
and stage (e.g., stage I, II, or III breast cancer patients, stage III colon
cancer, or stage II lung cancer) [9]. Fewer pediatric cancer patients
are diagnosed and treated each year compared with adults, preclud-
ing analyses of the childhood cancer QIs by subgroups based on
speciﬁc diagnoses and stage at diagnosis.
Limitations
While this is the ﬁrst set of operationally deﬁned QIs of a pediatric
cancer system to our knowledge [6], other jurisdictions need to
assess their local context to determine whether the QIs are appli-
cable to their health care systems and may wish to revise QIs or
measure a subset of applicable QIs. The use of modiﬁed Delphi panel
techniques has the potential for selection bias, and results are
based, and, therefore, dependent on the opinions of the group. We
believe that selection bias was minimized by the inclusion of
individuals nominated by each tertiary program and diverse stake-
holder representation. Formal qualitative analyses of Delphi panel
comments were not conducted for the purposes of this study. Last,
because only one parent and one survivor of childhood cancer
participated in the group consensus process, future iterations of QI
development and re-evaluation could consider including input from
additional parents and survivors to ensure that the perspectives of a
broader range of health system users are represented.Conclusions
The current study, together with our companion study on the
development of a set of proposed QIs of the childhood cancer
system [6], provides a basis for the implementation of QIs, both in
Ontario, Canada, and in other jurisdictions, based on evidence
and consensus opinions of a diverse childhood cancer stake-
holder community. These indicators will provide comparable and
standardized measures of the quality of Ontario’s childhood
cancer system and the development of benchmarks over time,
and across populations and jurisdictions, as well as evidence that
can be used to stimulate quality control and inform increased
health system change and accountability.Acknowledgments
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